Plague Pipeline

Single intranasal dose with cyclic dinucleotide

A US academic intranasal shot. Recombinant F1V displayed on biodegradable polyanhydride nanoparticles, given once in the nose with a cyclic dinucleotide adjuvant. Pneumonic model, 2019. Preclinical. No listing.

Stage chart

Preclinical

Phase 1

Phase 2

Phase 3

Licensed

Preclinical · pneumonic. Phase 3 is empty here, as it is for every programme in the set.

Years on the record

A mark at 2019. Labelled “2019” on the briefing. Not a forecast.

Analyst card

Challenge: Pneumonic model, 2019.
F1-negative strains: Not reported. The antigen is recombinant F1V, so both F1 and V are present.
Adjuvant: A cyclic dinucleotide, with the protein on polyanhydride nanoparticles.
Route: One dose in the nose.
Stability: Biodegradable particles. Shelf life is not stated.
Time to protection: Not reported. No time-to-protection figure is in the briefing.
Other threats: Plague only.
Survival figure: No survival percentage in the briefing.
Animal Rule: Preclinical. Not an Animal Rule file.

Pipeline record

Particle: Biodegradable polyanhydride nanoparticles carrying recombinant F1V.
Dose: One dose in the nose, with a cyclic dinucleotide adjuvant.
Model: Pneumonic. 2019. US academic. Preclinical. No listing.

News

Checking today’s headlines.

Latest intel

Checking Europe PMC.

PubMed

Checking today’s index.

Platform: Nanoparticle
Antigens displayed on a particle — a bacteriophage, or a degradable polymer — to change how the immune system meets them.
Who is paying: US — academic
Country: United States
What was tested: Pneumonic · intranasal
Stage: Preclinical · pneumonic
Date: 2019
Antigens named: F1V / LcrV